Customer Analytics for Every Stage of Investing

Request Demo

Better Data. Smarter Decisions.

Enhance your investment process with fresh ideas, increased confidence, and insight into companies and industries having the greatest potential for growth with HundredX. Our syndicated, consumer experience dataset is trusted by leading HFs, asset managers, private equity firms, and corporate strategy groups for proprietary and predictive outlooks.

A shopping cart icon in a blue square on a white background.

Idea Generation

Identify inflections in consumer and brand health, weeks before trends emerge in leading alternative data sets.

A line icon of an airplane on a blue background.

Due Diligence

Get up to speed quickly on new industries and ideas with insights into winners, losers, brand inflections, and reasons why.

A computer monitor icon in a blue square on a white background.

Portfolio Monitoring

Avoid being caught offsides, minimize risk, and have greater confidence in decisions with instant access to brand momentum across dozens of metrics.

Coverage

A shopping cart icon in a blue square on a white background.

Consumer

Retail, Restaurants, Grocers, Fashion and Apparel, Food, Beverages, Household Items, Autos

A line icon of an airplane on a blue background.

Leisure

Airlines, Hotels, Car Rental, Theme Parks, Cruise Lines, Fitness Centers and Gyms, Casinos, Movie Theaters

A computer monitor icon in a blue square on a white background.

TMT

Streaming, Social Media, Media, Video Games, Electronics, Appliances, Dating Apps, Wireless Providers, Cable and Internet, Online Betting, Sports Leagues, Ride Share, Food Delivery, OTAs

A mortar and pestle icon on a blue background.

Other

Banks, Credit Cards, Consumer Fin Tech, Insurance, Hospitals, Prescription Drugs, Dental

'Crowd Wisdom' Identifies Market Shifts Months in Advance

January 2023

CNBC: Netflix blows away expectations on subscriber numbers

Prior Consensus View

“Netflix shares sink amid report of sluggish start for ad tier, but one analyst says that’s no surprise."

— MarketWatch, December 2022

Wisdom of the Crowd

Usage Intent is now growing quicker for Netflix than for the industry. The only service to post gains in the last two months.

—HundredX, November 2022

A graph showing a number of lines on a white background.
A blue and white table with a red arrow pointing to a number.

January 2023

WSJ: "It's not just you, 5G is a big letdown"

Prior Consensus View

"5G technology introduction marks the beginning of a new era in connectivity that will impact almost every element of daily life."

— Deloitte, 2019

Wisdom of the Crowd

"5G is No. 16 out of 16 of what customers are talking about. What customers are talking about is coverage area and price."

— Rob Pace, HundredX CEO, The Dallas Morning News (July 7, 2021)

Featured insights from The Crowd Report™

View All
A stack of coins with the words consumer spending muted amid rising prices
November 7, 2024
Consumers are navigating still-high prices with resilience. HundredX analysis, based on millions of pieces of customer feedback from July 2021 through April 2023 across 3,200+ companies, indicates inflation remains persistent, but consumers are cautiously hanging on. New Consumer Price Index (CPI) data shows prices increased 3.4% in April from a year ago, compared to 3.5% in March, which highlights a slight easing in inflation month-to-month. Still, HundredX data shows that consumers still feel negative about prices in general, pointing to inflation’s stickiness and consumer frustrations over the consistently high prices of everyday goods. Generally, we’ve seen that changes to HundredX’s Price favorability index are typically inversely correlated with movement in the CPI levels (i.e., inflation) reported by the US government.
Starbucks shows weakness as consumers feel inflation fatigue
May 6, 2024
Sure, lattes, mochaccinos, and cappuccinos are pricey, but they taste delicious. For many consumers, the great taste of coffee shop coffee made it worth the cost. But customers at Starbucks aren't so sure the tradeoff is worth it anymore. Examining more than 420,000 pieces of feedback across the Quick, Fast, Casual (QFC) industry, including over 21,000 on Starbucks, we find: Starbuck's Purchase Intent 1,2 is down 3% over the past six months, with most of that dip occurring over the past few months. By contrast, Dunkin' Donuts has remained within a tight range over the past six months, as did an average of other, smaller coffee chains. Customers increasingly see less value in Starbucks. Starbuck's Value perception 3 fell 5% over the past six months, compared to just 1% for Dunkin' Donuts. However, it also fell 5% for the average of the smaller coffee chains. Coffee drinkers feel significantly unhappier about Starbuck's quality and taste. Starbuck's Taste perception fell 4% over the past six months, while rising 1% for competitors. Likewise, its Quality perception dipped 3% over the same time period (and 8% over the year). Ultimately, Starbuck's perceived drop in taste is leading inflation-weary consumers to say they plan to spend less at the coffee chain, as the value just isn't as good.
A person is holding a prescription medication in their hand
May 6, 2024
Ozempic once dominated the headlines, but GLP-1 competitor Mounjaro is winning over customers. GLP-1 drugs, used for treating diabetes and aiding in weight loss, are relatively new on the market yet have surged in popularity over the last year. They're becoming so popular that J.P. Morgan estimates that 30 million people in the US may be using a GLP-1 drug by 2030. This statistic presents a significant potential for early drug creator Novo Nordisk (Ozempic, Wegovy), and perhaps an even bigger one for Eli Lilly (Mounjaro, Zepbound). HundredX data indicates Eli Lilly is in a position to win over Novo Nordisk as Mounjaro's Usage Intent widens against the competition. Ozempic may have name recognition, but customers feel more positively about Mounjaro's effectiveness and lifestyle impact, even if they aren't excited about its high price. Examining 1,500 pieces of customer feedback across Mounjaro, Ozempic, and Wegovy, we find: GLP-1 users increasingly say they plan to use Mounjaro more, and Ozempic less . Mounjaro’s Usage Intent is up 19% since July, Wegovy’s is up 3%, and Ozempic has stayed within a tight range. Customers feel Mounjaro is more effective than competing drugs, but it’s harder to get . Mounjaro outperforms other GLP-1 drugs in effectiveness, lifestyle impact, and side effects. However, customers dislike its cost and availably more than competitors.